Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
Learn more about:
Related Clinical Trial
Disorders of Bone and Mineral Metabolism
QoL and Cognitive Function in Patients With Hypoparathyroidism
Theophylline Treatment for Pseudohypoparathyroidism – Children 2-12 Years Old
Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
Hypoparathyroidism in Denmark
Physiologic Regulation of FGF-23
Theophylline Treatment for Pseudohypoparathyroidism
Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
Glucose Homeostasis in Pseudohypoparathyroidism
Theophylline for Treatment of Pseudohypoparathyroidism
Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism
Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)